IP-10 Levels in Asthmatic Patients and Changes after Salmeterol and Fluticasone Propionate Powder Inhalation

Chen Gong,Jingmin Deng,Xuan Wei,Siqiao Liang
DOI: https://doi.org/10.3760/cma.j.issn.1673-436x.2011.009.006
2011-01-01
Abstract:Objective To investigate interleukin-17 (IL-17)'s role in the pathogenesis of bronchial asthma (asthma) we observed serum IL 17 levels in asthmatic patients and healthy persons,and examined the changes of serum IL-17 in asthmatic patients treated with salmeterol and fluticasone propionate powder.Methods Twenty-three asthmatic patients inhaling salmeterol and fluticasone propionate powder for a month were detected their lung functions,peripheral blood eosinophils,and serum IL 17,IL-10 (using enzyme-linked immune assay) at the 0th and 31th day respectively.Twelve healthy volunteers just measured serum IL-17,IL-10 and compared with the asthma group.Results Serum IL-17 levels in asthmatic patients before treatment were significantly higher than healthy volunteers (P < 0.01) and serum IL-10 levels were significantly lower than healthy volunteers (P <0.01).After 1 month treatment the levels of IL-17 decreased (P <0.01) while IL 10 increased (P <0.01).After treatment,the FEV1 %pred and PEF% pred of asthmatic patients increased (P < 0.01),while the eosinophils counts decreased (P <0.01).Serum IL17 levels correlated positively with eosinophils for asthmatic patients (P <0.01).Conclusions IL 17 may be involved in the pathogenesis of asthma and further indicated the complexity of the pathogenesis of asthma.Treatment with inhaled glucocorticosteroids and long-acting inhaled β32 agonists can significantly reduce serum IL-17 level in asthma. Key words: Asthma; Interleukin-17; Interleukin 10 ; Respiratory therapy
What problem does this paper attempt to address?